Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2,341 | 2,553 | 2,517 | 2,875 | 3,127 | 3,349 | 3,413 | 3,518 |
| Operating profit | $m | 580 | 663 | ||||||
| Net profit | $m | 431 | 421 | 188 | 190 | 359 | 410 | 386 | 504 |
| EPS reported | $ | 1.84 | 1.75 | ||||||
| Operating cashflow per share | $ | 1.66 | 1.87 | ||||||
| Capex per share | $ | 0.91 | 1.17 | ||||||
| FCF per share | $ | 0.75 | 0.70 | ||||||
| Free cash flow | $m | 165 | 148 | ||||||
| Net debt | $m | 1,197 | 1,677 | ||||||
| Book value equity | $m | 2,594 | 2,536 | ||||||
| Book value per share | $ | 11.65 | 11.60 | ||||||
| Number of shares | m | 222.68 | 218.63 | ||||||
| DPS (TTM paid) | $ | 0.83 | 0.85 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 11.33 | - | ||||||
| P/B LTM | x | 1.77 | 1.76 | ||||||
| P/S LTM | x | 1.37 | 1.31 | ||||||
| P/FCF LTM | x | 27.81 | 30.06 | ||||||
| EV/EBITDA LTM | x | 6.95 | 6.90 | ||||||
| EV/Sales LTM | x | 1.75 | 1.80 | ||||||
| Earnings Yield LTM | % | 8.83% | 8.54% | ||||||
| FCF Yield | % | 3.60% | 3.33% | ||||||
| Quality | |||||||||
| ROE | % | 15.82% | 15.05% | ||||||
| ROIC | % | 10.49% | 10.87% | ||||||
| Operating margin | % | 17.32% | 19.41% | ||||||
| Gross margin | % | 43.03% | 40.88% | ||||||
| FCF/Sales | % | 4.94% | 4.34% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +14.29% | -98.37% | ||||||
| Sales Growth YoY | % | +7.10% | +6.12% | ||||||
| Net Income Growth YoY | % | +14.33% | +4.03% | ||||||
| FCF Growth | % | -58.55% | -59.18% | ||||||
| Operating Profit Growth | % | -5.24% | +27.41% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 4.11% | 4.00% | ||||||
| Dividend Growth | % | +4.10% | +1.78% | ||||||
| Payout Ratio | % | 46.10% | 46.02% | ||||||
| FCF/Debt | x | 0.10 | 0.08 | ||||||
| Net Debt/EBITDA | x | 1.51 | 1.92 | ||||||
| EBIT/Net interest | x | 5.36 | 5.62 | ||||||
| Net debt/market cap | % | 26.02% | 37.64% | ||||||
| Net debt/Equity | x | 0.46 | 0.66 | ||||||
| Gross debt/equity | x | 0.62 | 0.78 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Hikma Pharmaceuticals PLC is a global pharmaceutical enterprise involved in the creation, production, promotion, and distribution of a wide array of generic, branded, and licensed medicinal solutions. These offerings are presented in various dosage formats, including solid, semi-solid, liquid, and injectable forms. The company's operations are strategically structured into three core segments: Injectables, Generics, and Branded. The Injectables division specializes in providing generic injectable medications, predominantly for hospital environments. Conversely, the Generics segment is responsible for supplying oral and other non-injectable generic pharmaceuticals to the consumer retail market. The Branded unit caters to both retail and hospital clients with its proprietary generic and in-licensed products. Hikma's comprehensive product portfolio addresses a broad spectrum of medical conditions, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory ailments. The firm boasts a substantial international presence, conducting business across the United Kingdom, the United States, the Middle East, North Africa, and various European countries. Founded in 1978, the company's corporate headquarters are situated in London, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Hikma Pharmaceuticals PLC (HIK.L)
Based on consensus from external analysts. Not Kvantra's opinion.
Hikma Pharmaceuticals PLC is a global pharmaceutical enterprise involved in the creation, production, promotion, and distribution of a wide array of generic, branded, and licensed medicinal solutions. These offerings are presented in various dosage formats, including solid, semi-solid, liquid, and injectable forms. The company's operations are strategically structured into three core segments: Injectables, Generics, and Branded. The Injectables division specializes in providing generic injectable medications, predominantly for hospital environments. Conversely, the Generics segment is responsible for supplying oral and other non-injectable generic pharmaceuticals to the consumer retail market. The Branded unit caters to both retail and hospital clients with its proprietary generic and in-licensed products. Hikma's comprehensive product portfolio addresses a broad spectrum of medical conditions, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory ailments. The firm boasts a substantial international presence, conducting business across the United Kingdom, the United States, the Middle East, North Africa, and various European countries. Founded in 1978, the company's corporate headquarters are situated in London, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free